Literature DB >> 17916747

Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.

Yuko Kimura1, Takashi Miwa, Lin Zhou, Wen-Chao Song.   

Abstract

Properdin is a positive regulator of alternative pathway (AP) complement. The current understanding of properdin function is that it facilitates AP complement activation by stabilizing the C3 convertase C3bBb. Properdin-deficient patients are susceptible to lethal meningococcal infection, but the mechanism of this selective predisposition is not fully understood. By gene targeting in the mouse, we show here that properdin is essential for AP complement activation induced by bacterial lipopolysacharride (LPS) and lipooligosacharride (LOS) and other, but not all, AP complement activators. LPS- and LOS-induced AP complement activation was abolished in properdin-/- mouse serum, and properdin-/- mice were unable to clear Crry-deficient erythrocytes, which are known to be susceptible to AP complement-mediated extravascular hemolysis. In contrast, zymosan- and cobra venom factor-induced AP complement activation, and classical pathway-triggered AP complement amplification were only partially or minimally affected in properdin-/- mice. We further show that the ability of human properdin to restore LPS-dependent AP complement activity in properdin-/- mouse serum correlated with the human properdin-binding affinity of the LPS. These results reveal a novel role of properdin in AP complement initiation and have implications for understanding the selective predisposition of properdin-deficient patients to meningococcal infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916747      PMCID: PMC2200840          DOI: 10.1182/blood-2007-05-089821

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Properdin system and immunity. II. Interaction of the properdin system with polysaccharides.

Authors:  L PILLEMER; M D SCHOENBERG; L BLUM; L WURZ
Journal:  Science       Date:  1955-09-23       Impact factor: 47.728

2.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

3.  Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.

Authors:  David D Kim; Takashi Miwa; Wen-Chao Song
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

Review 4.  Membrane complement regulatory proteins.

Authors:  David D Kim; Wen-Chao Song
Journal:  Clin Immunol       Date:  2005-12-09       Impact factor: 3.969

5.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2.

Authors:  Barbro Selander; Ulla Mårtensson; Andrej Weintraub; Eva Holmström; Misao Matsushita; Steffen Thiel; Jens C Jensenius; Lennart Truedsson; Anders G Sjöholm
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling.

Authors:  Zhe Sun; Kenneth B M Reid; Stephen J Perkins
Journal:  J Mol Biol       Date:  2004-11-05       Impact factor: 5.469

7.  Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.

Authors:  Georgia Sfyroera; Madan Katragadda; Dimitrios Morikis; Stuart N Isaacs; John D Lambris
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

8.  Inherited deficiency of properdin and C2 in a patient with recurrent bacteremia.

Authors:  E W Gelfand; C P Rao; J O Minta; T Ham; D B Purkall; S Ruddy
Journal:  Am J Med       Date:  1987-03-23       Impact factor: 4.965

9.  The properdin system and immunity. III. The zymosan assay of properdin.

Authors:  L PILLEMER; L BLUM; I H LEPOW; L WURZ; E W TODD
Journal:  J Exp Med       Date:  1956-01-01       Impact factor: 14.307

10.  The properdin system and immunity. VII. Alterations in properdin levels and resistance to infection in mice following the administration of tissue polysaccharides.

Authors:  L PILLEMER; M LANDY; M J SHEAR
Journal:  J Exp Med       Date:  1957-07-01       Impact factor: 14.307

View more
  59 in total

1.  The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Talat H Malik; Andrea Cortini; Daniele Carassiti; Joseph J Boyle; Dorian O Haskard; Marina Botto
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

2.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

3.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

4.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

5.  Properdin homeostasis requires turnover of the alternative complement pathway.

Authors:  Xiaobo Wu; Thomas Q Xu; John P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 6.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

Review 7.  Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host.

Authors:  Jennifer L Krauss; Jan Potempa; John D Lambris; George Hajishengallis
Journal:  Periodontol 2000       Date:  2010-02       Impact factor: 7.589

8.  Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Authors:  Kate Smith-Jackson; Kevin J Marchbank
Journal:  Ann Transl Med       Date:  2018-11

9.  Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.

Authors:  Takashi Miwa; Sayaka Sato; Damodar Gullipalli; Masaomi Nangaku; Wen-Chao Song
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

Review 10.  Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications.

Authors:  Alexander Laarman; Fin Milder; Jos van Strijp; Suzan Rooijakkers
Journal:  J Mol Med (Berl)       Date:  2010-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.